A new mechanism has been reported for detecting foreign material during early immune responses which may help detect elusive cancers.
List view / Grid view
Filter the results
Produced by Group A Streptococcus, researchers have discovered the S protein, which binds to the red blood cell membrane to avoid being destroyed by immune cells and could be a target for anti-virulence drugs.
A novel approach to better understand a basic defence mechanism of the immune system has been developed using the ISG15 protein which could lead to novel antimicrobial drugs.
Researchers have found that soft tissue sarcoma cells stop a key metabolic process which allows them to spread and restarting that process could leave these cancers vulnerable treatments.
Scientists have discovered that a plant-based compound called halofuginone activates a pathway that results in better antibodies and could improve the effectiveness of vaccines.
Researchers have found that MAIT immune cells respond rapidly to group A streptococcal infection, causing inflammation and toxic shock, which presents a therapeutic target.
A new discovery on how the immune system responds to malaria infection could lead to better treatments for hepatitis C, HIV and lupus.
Molecules made by immune cells to transport sodium lactate could be a target for treatment to stop the lactate build-up in chronic inflammatory disorders.
Scientists seek to design therapeutically more potent chemicals from alkaloids produced by the plant, Uncaria guianensis, which could aid in combatting tumours.
It has been discovered that papillomaviruses induce immunity that protects patients, which could lead to a novel method for preventing skin cancer using a vaccine based on T cells.
Molecules that are critical for T cells to travel to and populate the lungs have been identified which could strengthen vaccines against influenza.
A study has found that removing a particular kind of macrophage enables the immune system to attack tumours, providing a potential drug target.
A new study has shown that mutations in mitochondrial DNA induced by cell reprogramming may trigger an immune response.
A new mouse model, called 'wildlings', has been developed which better mirrors human immune responses than standard laboratory mice.